Biogen/Ionis’ Spinraza Data Shows Opportunity For Broad SMA Label
Both companies’ stocks surged Nov. 7 on positive data from a second Phase III trial showing the antisense drug improved motor function in children with later onset spinal muscular atrophy.
You may also be interested in...
Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.
Biogen’s Chief Commercial Officer Michel Vounatsos will succeed CEO George Scangos effective Jan. 6. The appointment of the longtime Merck executive appears to suggest a renewed emphasis on the commercial landscape for a big biotech that has recently played up R&D.
The latest drug development news and highlights from our FDA Performance Tracker.